                         SEQUENCE LISTING

<110>  THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE 
       SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
 
<120>  FULLY HUMAN ANTIBODY TARGETING PD1 FOR CANCER IMMUNOTHERAPY

<130>  4239-96972-02

<150>  US 62/346,694
<151>  2016-06-07

<160>  4     

<170>  PatentIn version 3.5

<210>  1
<211>  351
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  1
gaggtgcagc tggtggagtc cgggggaggt gtggtacggc ctggggggtc cctgagactc       60

tcctgtgcag cctctggatt cacctttgat gattatggca tgcactgggt ccgccaggct      120

ccaggcaagg ggctggagtg ggtggcagtt atatggtatg atggaagtaa taaatactat      180

gcagactccg tgaagggccg attcaccatc tccagagaca attccaagaa cacgctgtat      240

ctgcaaatga acagcctgag agctgaggac acggctgtgt attactgtgc gaaaaactac      300

tactacggta tggacgtctg gggccaaggg accacggtca ccgtctcctc a               351


<210>  2
<211>  117
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  2

Glu Val Gln Leu Val Glu Ser Gly Gly Gly Val Val Arg Pro Gly Gly 
1               5                   10                  15      


Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Asp Asp Tyr 
            20                  25                  30          


Gly Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 
        35                  40                  45              


Ala Val Ile Trp Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser Val 
    50                  55                  60                  


Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 
65                  70                  75                  80  


Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 
                85                  90                  95      


Ala Lys Asn Tyr Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr 
            100                 105                 110         


Val Thr Val Ser Ser 
        115         


<210>  3
<211>  324
<212>  DNA
<213>  Artificial Sequence

<220>
<223>  Synthetic polynucleotide

<400>  3
gacatccaga tgacccagtc tccatcctcc ctgtctgcat ctgtaggaga cagagtcacc       60

atcacttgcc gtgcgagtca gggcattagc aattctttag cctggtatca gcagaaacca      120

gggaaagccc ctaagctcct gatctacgat gcttccaatt tggaaacagg ggtcccatca      180

aggttcagtg gaagtggatc tgggacagat tttactttca ccatcagcag cctgcagcct      240

gaagatattg caacatatta ctgccaacag tataatagtt accccctgac tttcggcgga      300

gggaccaaac tggatatcaa acgt                                             324


<210>  4
<211>  108
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Synthetic polypeptide

<400>  4

Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 
1               5                   10                  15      


Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Gly Ile Ser Asn Ser 
            20                  25                  30          


Leu Ala Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 
        35                  40                  45              


Tyr Asp Ala Ser Asn Leu Glu Thr Gly Val Pro Ser Arg Phe Ser Gly 
    50                  55                  60                  


Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Leu Gln Pro 
65                  70                  75                  80  


Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Tyr Asn Ser Tyr Pro Leu 
                85                  90                  95      


Thr Phe Gly Gly Gly Thr Lys Leu Asp Ile Lys Arg 
            100                 105             


